Tag: LLP

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Treace Medical Concepts, Inc. (“Treace Medical” or the “Company”) (NASDAQ: TMCI).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Bitfarms Ltd. ("Bitfarms" or the "Company") (NASDAQ: BITF) and certain officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-02630, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Bitfarms securities between March 21, 2023 and December 9, 2024, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors who purchased UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ:URGN) securities to contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to discuss your rights or interests with respect to the securities fraud class action lawsuit against the Company.

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors of the July 7, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE:WST) securities during the period from February 16, 2023, through February 12, 2025 (“the Class Period”).